Although coronavirus is involved in approximately 20% of all colds, very few virology laboratories and close to zero pharmaceutical or biotech organizations were interested in this pathogen in any major way before January 2020. By late Summer 2020, more than 25,000 journal articles on coronavirus had appeared in respectable journals.
That so many research groups could respond as quickly as they did is as much a testimony to life science suppliers as to the labs themselves. Within a very short time, researchers had the tools and techniques they needed for experimentation, which, in turn, allowed the development of regulated human diagnostics and drugs to proceed at a breakneck pace.
This ebook, Accelerating SARS-CoV-2 Research with Novel Tools and Workflows, takes a look at some of reagents, assay kits, and methods that scientists have been using to advance their SARS-CoV-2 related research.